- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Diagnosis and treatment at the molecular level, made possible through nano-technology, is fueling new approaches for diagnostic and treatment solutions in the healthcare sector. Never before accuracy is required to detect contaminants which can affect production capability and efficacy. Neutron Activation Analysis (NAA) may improve outputs by detecting contaminants early - reducing wasted time and materials.
This paper will address:
• The impact of nano-delivery requirements in healthcare
• A summary of science including the role of nano-technology in detection and delivery and the role of high-purity analysis.
• Conclusion - The key takeaway of how high-quality, stringent testing might drive industry.
Applications of nano-technologies in healthcare
Demand for high performance, targeted products is fueling growth across multiple industries, and nowhere as significantly in healthcare. Developments in measurement and application of nano-technology, a field of applied sciences and technology which centers on the control of matter at a molecular or atomic level, have made commercial applications possible. The field gets its name from the measurement of nanometers that typically defines the size of devices and applications used to manipulate matter.
Nano-technology can deliver never before envisioned efficiencies in virtually every industry. Primary healthcare fields currently leveraging the technologies are:
1. Bio-medical, particularly in the areas of tumor detection and treatment
2. Pharmaceutical, for delivery of treatment at a cellular level
3. Research, primarily in determining causes and detection of diseases affecting the central nervous system (e.g. Alzheimer's and Parkinson's)
Much of the growth in health care is projected in imaging agents and in targeted pharmaceutical delivery, particularly in cancers. A study by the Freedonia Group estimates the current US nanotechnology market for healthcare at $906 million, projected to grow at 48% annually through 2009.
Three key areas of new growth are referenced in the study to drive demand to new levels:
1. Product development, driven by developments in nanoparticles, nanoarrays, nanotubes, dendrimers.
2. Application development in pharmaceuticals, devices and diagnostic equipment
3. Advances in indication application (e.g. diagnostics for central nervous systems)
Funding for research in the field of nanomedicine was set up directly by the US National Institutes of Health in 2005.
About Elemental Analysis, Inc.
Elemental Analysis, Inc. (EAI), a privately held company, is affiliated with our sister company, Element Analysis Corp (EAC), which provided industry with the first commercially dedicated PIXE laboratory in the world. EAI recognized the need for lower limits of detection and higher levels of accuracy – without compromising customer service. Since December 2000, EAI has provided all segments of industry with quick turn-around times and set the standard for reporting accuracy.
EAI provides both non-destructive and state of the art forms of analytical chemistry with limits of detection ranging from sub-percent, to as low as parts-per-quadrillion.
For more information, please click here
Elemental Analysis, Inc.
2101 Capstone Drive
Lexington, KY 40511
800-563-7493 (Toll Free)
Copyright © Elemental Analysis, Inc.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Leti Announces Launch of First European Nanomedicine Characterisation Laboratory: Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval July 1st, 2015
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers